Daily Archives: September 3, 2010

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Medicines for Malaria Venture (MMV) Joins The Pool for Open Innovation Against Neglected Tropical Diseases

Leave a comment

Global Health Progress (GHP) is pleased to highlight the announcement that the not-for-profit public-private partnership Medicines for Malaria Venture (MMV) will became the first product development partnership (PDP) to contribute intellectual property to The Pool for Open Innovation against Neglected Tropical Diseases (The Pool).

MMV joined GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in providing intellectual property to The Pool. Discussing the decision, Professor Patrick Nef, Executive Vice President of Business Development at MMV, states, “In this way we hope to make fully available the know-how and technologies, assembled by MMV against malaria, for the research and development of innovative and efficacious treatments for other neglected diseases.”

By emphasizing a more accessible approach to intellectual property and know-how, The Pool facilitates access to patents and/or technologies for organizations that want to conduct research on treatments and motivates innovative and efficient drug discoveries and developments for neglected diseases.

The Pool is administered by BIO Ventures for Global Health (BVGH). It’s accessible to industry, non-profit institutions, and academic researchers who conduct research and drug development activities that deliver real benefits for patients in the least developed countries of the world.

Global Health Progress echoes the sentiment that MMV’s contribution of patents to The Pool, resulting from its research for new antimalarials, is an important milestone from an organization that plays a major role in leading the development of new therapeutics for malaria.

Global Health Progress supports the continuing partnership between not-for-profit public-private partnerships and research-based biopharmaceutical companies as a way to fight neglected tropical disease through targeted research and development (R&D), improving access to critical medicines and providing key intellectual property.

Via EPR Network
More Healthcare press releases

Alternative medicine, Business of Medicine, Drugs, Health Products, Healthcare, Healthcare Products, Medicine, Pharmaceuticals

Zetathermide Proven to Generate Hi Levels of Far Infrared at Very Low Temperatures

Leave a comment

The ZTG Group has completed it’s six year development cycle and independent 3rd party testing of a new material titled ZetathermideTM. Zetathermide has been proven effective in emitting high levels of Far-Infrared at very low temperatures.

The completion of Zetathermide’s development is extremely relevant to the fields of chiropractic care, physical therapy, massage, fitness as well as other fields associated with discomfort management and general and health and wellness.

Zetathermide allows for a patient or user to achieve many of the benefits of heat therapy without the discomfort or inconvenience of high temperature. Simply by placing this material directly on the skin, the body may respond as if the user had applied heat. It can be used 24 hours a day with no dangerous side effects other than an unlikely allergic reaction.

Zetathermide is remarkable in that it has been found to work as a cosmic “tuning fork” or converter of energy without the need for electricity or any other artificial input. It can be used in its purest state or as an additive to silicone, plastics, ceramics, wood, resins, paint or any other substance that transforms from a liquid to solid state.

Via EPR Network
More Healthcare press releases